BioVie BIVI 深 滬
已收盤 11-06 16:00:00 美东时间
1.33
+0.120
+9.92%
華盛通- 最 高1.38
- 今 開1.25
- 成交量 18.44万股
- 最 低 1.2301
- 昨 收 1.21
- 總市值 1154.80万
- 52周最高 3.79
- 市盈率 靜 --
- 換手率 2.12%
- 52周最低 0.82
- 委 比 52.13%
- 總股本 868.27万
- 歷史最高 4609.80
- 量 比 0.06
- 振 幅 12.39%
- 歷史最低 0.82
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioVie Announces $4.74M Registered Direct Offering And Concurrent Private Placement
BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for t...
11-04 21:06
BioVie Invited To Present Late-Breaking Oral Presentation At The 4th Long Covid International Conference, November 12-13
Dr. Penelope Markham, BioVie’s Senior Vice President and Program Lead for Long COVID, will share the presentation titled "Bezisterim Improves Fatigue, Post-Exertional Malaise, and Cognition in Prespecified High-Symptom-Burden Subgroups of the Phase 2 Randomized ADDRESS-LC Trial in Long COVID" during...
11-02 22:02
BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026
BioVie Inc. has been invited to present late-breaking data on its drug Bezisterim at the 4th Long COVID International Conference. The presentation will highlight findings from the Phase 2 ADDRESS-LC trial, showing significant improvements in fatigue, post-exertional malaise, and cognition in high-symptom-burden patients with Long COVID. Bezisterim, which targets neuroinflammation, has demonstrated potential in reducing symptoms linked to persiste...
11-02 14:00
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
BioVie Inc. has been invited to present at the 2026 RECOVER-TLC Workshop, where Dr. Penelope Markham will share results from the Phase 2 ADDRESS-LC trial evaluating bezisterim for Long COVID's neurological symptoms. The trial showed consistent improvement trends in fatigue, post-exertional malaise, and cognitive impairment, particularly in patients with severe baseline symptoms. Bezisterim demonstrated a favorable safety profile. The RECOVER-TLC ...
10-26 12:00
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
BioVie Inc. announced that two abstracts from its ADDRESS-LC Phase 2 trial for Long COVID and SUNRISE-PD Phase 2 trial for Parkinson’s Disease have been accepted for presentation at ANA2026 in San Diego, October 17-20, 2026. The studies will be presented as posters. Bezisterim (NE3107), the company’s investigational drug, targets neuroinflammation and insulin resistance, showing potential benefits in reducing inflammation and improving symptoms i...
10-14 12:00
BioVie’s NE3107 Long COVID Trial Completion: What Investors Should Watch Next
Biovie Inc. ($BIVI) announced an update on their ongoing clinical study. BioVie...
09-23 00:30
What's Going On With BioVie Stock on Tuesday?
Clinical-stage biopharmaceutical firm BioVie Inc. (NASDAQ:BIVI) stock is trading lower after the company shared topline results from its Phase 2 ADDRESS-LC study evaluating bezisterim in Long COVID patients. Pre-specified subgroup analyses submitted to the FDA before unblinding showed that participa...
09-16 00:21
BioVie Enters Sales Agreement With Alliance Global Partners For Up To $6,464,341 Of Stock
On September 11, 2026, BioVie Inc., a Nevada corporation (the "Company"), entered into a sales agreement (the "Sales Agreement") with A.G.P./Alliance Global Partners (the "Agent"), pursuant to which the Company may issue and sell from time to time, to or through the Agent, shares of the Company’s Cl...
09-14 18:13
宝莱特新注册《BioView C100系列麻醉视频喉镜主控软件V1.0》项目的软件著作权
证券之星消息，近日宝莱特（300246）新注册了《BioView C100系列麻醉视频喉镜主控软件V1.0》项目的软件著作权。今年以来宝莱特新注册软件著作权9个。
09-09 04:25
